DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study

Kim, S; Vendrely, V; Saint, A; André, T; Vaflard, P; Samalin, E; Pernot, S; Bouché, O; Zubir, M; Desrame, J; de la Fouchardière, C; Smith, D; Ghiringhelli, F; Vienot, A; Jacquin, M; Klajer, E; Nguyen, T; Francois, E; Taieb, J; Le Malicot, K; Vernerey, D; Meurisse, A; Borg, C

Kim, S (通讯作者)，CHU Besancon, Clin Invest Ctr, INSERM CIC 1431, 1431, Besancon, France.;Kim, S (通讯作者)，Univ Bourgogne Franche Comte, INSERM Unit 1098, Besancon, France.;Kim, S (通讯作者)，Sanat Allende, Dept Oncol, Cordoba, Argentina.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023; 12 (1):

Abstract

Triplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospec......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索